Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors
Clinical Breast Cancer · 2025-02 · 25 (2) · e159-e169.e2
DOI: 10.1016/j.clbc.2024.08.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025-02. Verfasst von Yada Kanjanapan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Canberra Hospital, Canberra, Australia; Australian National University Medical School, Australian National Univer…. Hauptthemen laut MEDLINE: Aminopyridines, Benzimidazoles, Breast Neoplasms, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Adjuvant CDK4/6 inhibitors abemaciclib and ribociclib improved disease-free survival (DFS) added to endocrine therapy in hormone receptor (HR)-positive HER2-negative early breast cancer (EBC), in monarchE (NCT03155997) and NATALEE (NCT03701334) trials respectively. We assessed the proportion and outcome of EBC patients qualifying for adjuvant CDK4/6 inhibitors in the real-world. METHODS: Consecutive female patients with HR-positive HER2-negative EBC between 1997 and 2017 from the Australian Capital Territory and South-East New South Wales Breast Cancer Treatment Group registry were analyzed. Patients eligible for abemaciclib had ≥4 axillary nodes involved or 1-3 nodes plus primary >5 cm or grade 3. Ribociclib eligibility was defined as node-positive and node-negative with primary >5 cm or >2 cm grade 3. RESULTS: Of 3840 patients, 671 (17.5%) were abemaciclib-eligible and 1587 (41.3%) ribociclib-eligible . The 5-year DFS was 77% and 94% in abemaciclib-eligible and noneligible registry patients respectively (HR 2.6, 95% CI 2.26-3.05, P < .001). The 5-year DFS was 86% and 97% in ribociclib-eligible and noneligible registry patients respectively (HR 1.92, 95% CI 1.67-2.19, P < .001). Compared with monarchE trial patients, abemaciclib-eligible registry patients were older (median 55 years in registry vs. 51 years in trial), with lower nodal burden (≥4 nodes in 44% in registry vs. 60% in trial). There were more stage III cancers in NATALEE trial patients (60%) than ribociclib-eligible registry patients (24%). CONCLUSIONS: Many women with EBC will qualify for adjuvant CDK4/6 inhibitors (17.5% abemaciclib, 41.3% ribociclib) with resource and workforce implications. In the real-world setting, a greater proportion of adjuvant CDK4/6-eligible patients have lower stage disease, therefore the absolute benefit from treatment may be smaller than estimated by the trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Canberra Hospital, Canberra, Australia; Australian National University Medical School, Australian National University, Canberra, Australia. Electronic address: yada.kanjanapan@act.gov…
- Epidemiology Section, Data Analytics Branch, Australian Capital Territory Health Directorate, Canberra, Australia.
- Epidemiology Section, Data Analytics Branch, Australian Capital Territory Health Directorate, Canberra, Australia; National Centre for Epidemiology and Population Health, Australian National University, Canberra, Austra…
- Department of Medical Oncology, The Canberra Hospital, Canberra, Australia; Australian National University Medical School, Australian National University, Canberra, Australia.
Zitieren
APA
Kanjanapan, Y., Anderson, W., Smith, M., Green, J., Chalker, E., & Craft, P. (2025). Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors. Clinical Breast Cancer, 25(2), e159-e169.e2. https://doi.org/10.1016/j.clbc.2024.08.022
Vancouver
Kanjanapan Y, Anderson W, Smith M, Green J, Chalker E, Craft P. Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors. Clinical Breast Cancer. 2025;25(2):e159-e169.e2. doi:10.1016/j.clbc.2024.08.022
BibTeX
@article{Kanjanapan2025,
author = {Kanjanapan, Yada and Anderson, Wayne and Smith, Mirka and Green, Jenny and Chalker, Elizabeth and Craft, Paul},
title = {Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors},
journal = {Clinical Breast Cancer},
year = {2025},
volume = {25},
number = {2},
pages = {e159--e169.e2},
doi = {10.1016/j.clbc.2024.08.022}
}
EUVIMED